drugset

drugset / Trial / NCT06050239

Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer

NCT06050239 ↗

Phase 0 Unknown 10 enrolled Nanjing First Hospital, Nanjing Medical University

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of 177Lu-PSMA-0057 in metastatic prostate cancer.

Timeline

Start: 2023-03-01
Primary completion: 2025-03-01
Completion: 2025-03-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	177Lu-PSMA-0057	Other / unclassified	—	—

Indications